Search

Myriam Aouadi

from Worcester, MA
Age ~48
Get Report
Also known as:
Myriam Aoudi
Connected to:
Anis Aouam, 54Mohamed E Aouam, 42Elsie Aouate, 103Kim K Aouchiche, 65Massinissa Aouchiche, 39Dani A Aoude, 48Fatima Aoude, 45George Y Aoude, 35Houssam M Aoude, 53Mona Aoude, 75

Myriam Aouadi Phones & Addresses

  • Worcester, MA
  • Natick, MA

Work

Company: University of massachusetts Jan 2012 Address: Greater Boston Area Position: Assistant professor

Education

Degree: Ph.D School / High School: University of Science Nice-Sophia-Antipolis 2001 to 2005 Specialities: Biology

Skills

Molecular Biology • Cell Biology • Animal Models • Management • Sirna • Physiology • Metabolism • Immunology • Transfection • Cell Signaling • Qpcr • Inflammation • Laboratory • In Vitro • Cell • In Vivo • Immunohistochemistry • Flow Cytometry • Mouse Models • Molecular Cloning

Languages

English • French

Industries

Higher Education

Resumes

Resumes

Myriam Aouadi Photo 1

Principal Investigator

View page
Location:
Worcester, MA
Industry:
Higher Education
Work:
University of Massachusetts - Greater Boston Area since Jan 2012
Assistant Professor
umass Apr 2009 - Jan 2012
Research assistant professor
UMass Medical School Jun 2006 - Apr 2009
Post-doctoral Fellow
Education:
University of Science Nice-Sophia-Antipolis 2001 - 2005
Ph.D, Biology saint exupery 1992 - 1996
baccalaureat
Skills:
Molecular Biology
Cell Biology
Animal Models
Management
Sirna
Physiology
Metabolism
Immunology
Transfection
Cell Signaling
Qpcr
Inflammation
Laboratory
In Vitro
Cell
In Vivo
Immunohistochemistry
Flow Cytometry
Mouse Models
Molecular Cloning
Languages:
English
French

Publications

Us Patents

Encapsulated Nanoparticles For Nucleic Acid Delivery

View page
US Patent:
20090226528, Sep 10, 2009
Filed:
Oct 29, 2008
Appl. No.:
12/260998
Inventors:
MICHAEL P. CZECH - WESTBOROUGH MA, US
GARY R. OSTROFF - WORCESTER MA, US
MYRIAM AOUADI - WORCESTER MA, US
Assignee:
UNIVERSITY OF MASSACHUSETTS - BOSTON MA
International Classification:
A61K 9/50
A61K 38/02
A61K 31/7088
A61K 31/7105
A61K 48/00
C12N 5/06
A61P 3/00
A61P 3/10
A61P 9/00
A61P 37/00
A61P 25/00
A61P 31/00
US Classification:
424491, 424490, 514 12, 514 44 R, 514 44 A, 424493, 424497, 435375, 424 937
Abstract:
Methods and compositions for delivering agents (e.g., gene silencing agents) and molecules to cells using yeast cell wall particles are presented herein. Embodiments of the invention are particularly useful for the delivery of nucleic acids (e.g., siRNAs) to cells.

Peptide-And Amine-Modified Glucan Particles For Delivery Of Therapeutic Cargoes

View page
US Patent:
20160184449, Jun 30, 2016
Filed:
Feb 28, 2014
Appl. No.:
14/763308
Inventors:
- Boston MA, US
Jessica L. Cohen - Worcester MA, US
Myriam Aouadi - Worcester MA, US
Yuefei Shen - Boston MA, US
International Classification:
A61K 47/48
C12N 15/113
A61K 36/064
A61K 38/14
A61K 48/00
Abstract:
The present invention generally relates to peptide-modified glucan particles (PcGPs) and/or amine-modifies glucan particles (amGPs) for use in delivering payload molecules, in particular, nucleic acid payload molecules, to cells. The invention relates to particular peptides and small molecule amines which are ideally suited for use in the pcGPs and amGPs of the invention, respectively. Preferred aspects of the invention feature a single-component delivery vehicle comprising the pcGPs or amGPs and siRNA, for use as an siRNA delivery vehicle. Methods of making such particles and methods of using such particles, for example, for in mediating in vitro and in vivo gene silencing are disclosed herein.

Glucan-Encapsulated Sirna For Treating Type 2 Diabetes Mellitus

View page
US Patent:
20160138028, May 19, 2016
Filed:
Jun 24, 2014
Appl. No.:
14/900951
Inventors:
- Bethesda MD, US
- Boston MA, US
Michael Paul CZECH - Worcester MA, US
Myriam AOUADI - Worcester MA, US
International Classification:
C12N 15/113
Abstract:
Compositions comprising glucan-encapsulated siRNA directed against a region of the gene encoding the human CB1 receptor for use in the treatment of type 2 diabetes mellitus in a human subject. Additionally, methods for treating type 2 diabetes mellitus in a subject, comprising administering to the subject a composition comprising glucan-encapsulated siRNA directed against the CB1 receptor.
Control profile
Myriam Aouadi from Worcester, MA, age ~48 Get Report